# 2026-13480: Government Licenses Viral Peptide to Fight Liver Cancer

2026-13480, Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-07-02; PRIA reads it as touching household money (as of 2026-07-09).

- Canonical: https://policyrisk.com/federal-register/2026-13480
- As of: 2026-07-09
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13480
- Title: Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 40548
- Published: 2026-07-02
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-09

## In one line

Government Licenses Viral Peptide to Fight Liver Cancer

## Summary

The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.

## Abstract

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.

## Effects PRIA read

- NIH Offers CE1 Peptide License: benefit, medium. The National Cancer Institute (NCI) is offering a license and co-development opportunities for a viral peptide (CE1) intended for hepatocellular carcinoma (HCC) prevention and treatment (NIH Reference Number E-023-2024). The technology is at the Discovery stage and is being offered for commercial d…
- Potential New HCC Vaccine/Therapy: benefit, high. Researchers at the NCI report that a synthetic CE1 peptide can elicit T cell responses against HCC cells and could be developed as an immunotherapy or CE1-based HCC vaccine. The notice says such novel treatments could offer substantial public health benefits for people at risk of or living with hep…
- New Diagnostic and Monitoring Uses: benefit, medium. The NCI lists potential commercial applications including a predictive biomarker for HCC risk, a serological response test, patient stratification for CE1-based therapy, and tools to monitor vaccine efficacy. These applications could be developed and licensed for clinical use alongside CE1-based th…

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-13480 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/02/2026-13480/government-owned-invention-available-for-license-a-conserved-viral-peptide-for-use-in-cancer)
- [2026-13480 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-02/pdf/2026-13480.pdf)

## Related
- [Previous: 2026-13479, Government Owned Invention Available for License: Chimeric VLP Vaccines To Prev…](https://policyrisk.com/federal-register/2026-13479)
- [Next: 2026-13486, Implementing Voluntary Agreements Under the Defense Production Act](https://policyrisk.com/federal-register/2026-13486)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13480 (as of 2026-07-09).
